tiprankstipranks
TipRanksStock Market NewsILMN NewsLeerink Partners Remains a Buy on Illumina (ILMN)
Blurbs

Leerink Partners Remains a Buy on Illumina (ILMN)

Leerink Partners analyst Puneet Souda maintained a Buy rating on Illumina (ILMNResearch Report) on July 22. The company’s shares closed last Wednesday at $492.22.

According to TipRanks.com, Souda is a 5-star analyst with an average return of 18.8% and a 66.1% success rate. Souda covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, AbCellera Biologics, and Castle Biosciences.

Currently, the analyst consensus on Illumina is a Moderate Buy with an average price target of $442.50, which is a -9.0% downside from current levels. In a report issued on July 14, Canaccord Genuity also maintained a Buy rating on the stock with a $515.00 price target.

See today’s analyst top recommended stocks >>

Based on Illumina’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.09 billion and net profit of $147 million. In comparison, last year the company earned revenue of $859 million and had a net profit of $173 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incorporated in 1998, Illumina, Inc. is a California-based company which develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. Its products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The company’s products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting.

Read More on ILMN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More